& RYSE**
Good day, 360!
Here are some of our top movers today. Don’t forget Jason’s NEW $2000 Small Account Journey starts today. Get in for a low as $197 🔥. Be the best prepared trader on the Street!
FOCUS LIST🔎
PPBT – Up over 70% in the pre-market after reporting positive final results from randomized Phase 2 study of CM24 in second line pancreatic cancer
SNTI – Up over 80% in pre after announcing positive initial clinical data in Phase 1 clinical trial of SENTI-202, a logic gated, selective CD33/FLT3- targeting CAR-NK Cell therapy for the treatment of relapsed/refractory Hematologic Malignancies Including AML
VMAR- Up over 14% in pre after announcing production partnership with Massimo Marine Announce for first commercial electric pontoon platform
Invest Alongside Top Politicians And Famous Hedge Fund Managers
Over $380 million invested and 9M trades, on Autopilot.
Join the 900,000+ investors who love Autopilot.
More than $1.3 billion in trade volume since launching last year.
HOTLIST🔥
PPBT – Up over 70% in the pre-market after reporting positive final results from randomized Phase 2 study of CM24 in second line pancreatic cancer
Purple Biotech Ltd. (PPBT) is a clinical-stage company that focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
In the pre-market this morning, the company reported positive final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).
Highlights include:
Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints
A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with median PFS improvement of 2.9 months and improvement in the treatment arm over the control in ORR of 50% vs. 0%.
Phase 2b clinical study is planned in multiple selected indications, potentially targeting patients based on biomarkers
Shares of PPBT traded up over 70% in the pre-market in reaction to the news.
The $4.90 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $5.60, $6, $6.50 and then the pre-market high at $6.70. Beyond that $7.80, $8.30 and $10 come into play.
Below $4.90, targets to the downside are $4.65, $4, $3.81, $3.65 and then a gap fill at $3.36.
SNTI – Up over 80% in pre after announcing positive initial clinical data in Phase 1 clinical trial of SENTI-202, a logic gated, selective CD33/FLT3- targeting CAR-NK Cell therapy for the treatment of relapsed/refractory Hematologic Malignancies Including AML
Senti Biosciences Inc. (SNTI) operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
In the pre-market this morning, the company announcedreported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (“CAR-NK”) investigational cell therapy, for the treatment of relapsed/refractory (“R/R”) hematologic malignancies including acute myeloid leukemia (“AML”).
Highlights include:
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile
– Dose escalation is continuing with additional response and durability data expected in 2025
Shares of SNTI traded up over 80% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $6.34. Above it, targets to the upside are $7, $7.43 and $8.48.
Below $6.34, targets to the downside are $5.50, $4.50, $4, $3.70, $3, $2.50 and then a gap fill at $2.16.
sponsored by RYSE**
Amazon Bets Big on Smart Homes, You Can Too
VCs know how difficult it is to spot promising early investment opportunities. Even the Sharks from Shark Tank declined the offer to buy 10% of Ring for $700,000 – a decision they would regret when Amazon acquired Ring, turning the $700,000 into $10M!
RYSE is the smart-home brand poised to follow a similar trajectory. The founder pitched on Canada’s version of Shark Tank, Dragons’ Den and received two offers – it seems the Dragons’ learned from the Sharks’ mistakes. Don’t make the same mistake the sharks did.
VMAR- Up over 14% in pre after announcing production partnership with Massimo Marine Announce for first commercial electric pontoon platform
Vision Marine Technologies Inc. (VMAR) designs, develops, manufactures, sells, and rents electric boats in Canada, the United States, and internationally.
Over the weekend, the company announced a milestone partnership with Massimo Marine, the marine division of Massimo Group (MAMO). This collaboration will produce a fully integrated 30-foot electric pontoon platform designed for commercial and recreational markets. As part of Vision Marine’s strategic shift to offer complete electric boats directly to consumers, this partnership represents a key step in rapidly delivering high-quality electric marine products to market.
In 2023, pontoon boat sales reached 115,000 units, a 5% increase over 2022 (https://pontoonboatguy.com/). This robust market growth reflects the demand for versatile and family-friendly watercraft.
Shares of VMAR traded up over 14% in the pre-market in reaction to the news.
The $2.40 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.80, $3, $3.20, $3.40, $3.60 and then the pre-market high at $3.90.
Below $2.40, targets to the downside are $2.35 and then a gap to fill at $2.20.
MARKET NEWS 📰
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
**ISSUER-PAID ADVERTISEMENT: This Issuer has previously paid RagingBull.com, LLC (“Raging Bull”) thirty thousand dollars in cash and thirty thousand in shares to run advertisements enhancing public awareness of the company. Raging Bull is currently invested in this company. RagingBull is currently an affiliate for RYSE.If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
